Skip to main content
OpenTrials

Clinical trial condition

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Explore clinical trials studying Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma trial results

Active, Not Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

NCT03703050

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • Rigshospitalet Copenhagen, Denmark
  • Hôpital Trousseau Paris, France
  • Gustave Roussy Villejuif, Val de Marne, France
  • CHU Bordeaux Hopital Pellegrin Bordeaux, France
View all 13 locations
View Trial Details

Related conditions